Celyad Oncology SA

ENXTBR:CYAD Stock Report

Market Cap: €27.8m

Celyad Oncology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Matt Kane

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Dec 31
We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

CEO

Matt Kane (47 yo)

less than a year

Tenure

Mr. Matthew R. Kane, also known as Matt, is Chief Executive Officer of Celyad Oncology SA since October 1, 2024 and its Executive Director since December 2024. Mr. Kane is the Chief Executive Officer and D...

Leadership Team

NamePositionTenureCompensationOwnership
Michel E. Lussier
Co-Founder & Non-Executive Directorno data€96.31k0.38%
€ 104.9k
Matthew Kane
CEO & Executive Directorless than a yearno datano data
David Georges
Vice President of Finance & Administration2.5yrsno datano data
Sara Zelkovic
Communications & Investor Relations Directorno datano datano data
An Phan
Head of Legal2.5yrsno datano data
Hannes Iserentant
Head of Intellectual Property2.5yrsno datano data
Eytan Breman
Head of R&D2.6yrsno datano data
Philippe Dechamps
Corporate Secretaryno datano datano data

2.5yrs

Average Tenure

48yo

Average Age

Experienced Management: CYAD's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michel E. Lussier
Co-Founder & Non-Executive Director18yrs€96.31k0.38%
€ 104.9k
Matthew Kane
CEO & Executive Directorless than a yearno datano data
Hilde Windels
Independent Chairwoman of the Board8yrs€101.10kno data
Serge Goblet
Non-Executive Director17yrs€15.50k0.14%
€ 37.6k
Margo Roberts
Member of Scientific Advisory Boardno data€10.00kno data
Hinrich Abken
Member of Scientific Advisory Board8.8yrsno datano data
Marco Davila
Member of Scientific Advisory Board8.8yrsno datano data
Marina Blagovic
Independent Director4.7yrs€49.50kno data
Dominic Piscitelli
Independent Director4.7yrs€69.50kno data
Ami Shah
Non-Executive Director3.1yrsno datano data
Ann Ager
Member of Scientific Advisory Boardno datano datano data
Christopher LiPuma
Non-Executive Director3yrsno datano data

6.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: CYAD's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:54
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celyad Oncology SA is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
John SavinEdison Investment Research
Edward WhiteH.C. Wainwright & Co.